Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830

Core Insights - Zealand Pharma announced positive Phase 1a topline results for ZP9830, a Kv1.3 channel blocker, indicating favorable safety and tolerability in healthy male participants [2][4] Group 1: Phase 1a Trial Results - The Phase 1a trial was a single ascending dose (SAD) study designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ZP9830 [2][5] - ZP9830 was well tolerated with no dose-limiting safety findings or serious adverse events reported [3][8] - Pharmacokinetic parameters showed a dose-proportional increase, and the intravenous cohort demonstrated high bioavailability of the subcutaneous formulation [3][8] Group 2: ZP9830 Overview - ZP9830 is a selective Kv1.3 channel blocker with potential applications in treating various immune-mediated inflammatory diseases [6][8] - The Kv1.3 channel is selectively upregulated on effector memory T cells, which are involved in autoimmunity and chronic inflammation [6][7] Group 3: Company Background - Zealand Pharma focuses on advancing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise [8][9] - The company has successfully developed multiple drug candidates, with two products already on the market and three in late-stage development [9]